1 published article · Updated continuously
18 trials tracked for Cervical Adenocarcinoma: 4 in phase 3 or 4 and 3 with published results. The most-cited published study has 1504 citations.
Showing the 18 most-cited and recently-updated of 18 trials. Browse the full registry →
Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.
Clinical investigations into cervical adenocarcinoma have evaluated several systemic therapies, including Bevacizumab and Atezolizumab. In a Phase 3 trial of Bevacizumab (N=452), the study was established as part of the standard evidence base 1. A separate Phase 2 trial evaluating Bevacizumab (N=60) reported that zero subjects experienced treatment-related serious adverse events or Grade 3+ adverse events within the first 90 days of treatment 16.
Atezolizumab was evaluated in two trials. In a Phase 2 study (N=11), 36.4% of participants experienced adverse events 5. A Phase 1 trial (N=40) reported that 21.43% of participants experienced dose-limiting toxicities, while the incidence of Grade 3 or higher adverse events during the treatment period ranged from 0% to 6% across various cohorts; this study also recorded disease-free survival at 2 years as 68.4% and 52.9% respectively 18.
Chemotherapeutic agents including Carboplatin and Cisplatin have been studied in Phase 3 trials. For Carboplatin (N=926), the reported 5-year overall survival rates were 71% and 72%, while 5-year progression-free survival rates were 62% and 63%; Grade 3 or higher adverse events in the first year ranged from 1% to 14% 2. For Cisplatin, Phase 3 trials were conducted with cohorts of N=340 3 and N=513 4.
AI synthesis of 7 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.
